Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma

Emiddio Barletta, Francesco Fiore, Bruno Daniele, Alessandro Ottaiano, Roberto D'Angelo, Ettore Ferrari, Roberta Formato, Anna Tortoriello, Giacinto Turitto, Giovanni Salvatore Bruni, Sandro Pignata, Rosario Vincenzo Iaffaioli

Research output: Contribution to journalArticlepeer-review


The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.

Original languageEnglish
Pages (from-to)782-787
Number of pages6
JournalFrontiers in Bioscience
Issue number1 P.447-888
Publication statusPublished - 2006


  • Intraarterial Chemotherapy
  • Pancreatic Adenocarcinoma
  • Second-Line Chemotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this